OXC-101 is under clinical development by Oxcia and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how OXC-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OXC-101 (TH-1579/Karonudib) is under investigation for the treatment of metastatic melanoma, relapsed and refractory acute lymphocytic leukemia, acute myeloid leukemia, diffuse large B-cell lymphoma, burkitt lymphoma, multiple myeloma, myelodysplastic syndrome and solid malignant tumors. The drug candidate is administered through oral route as a solution. It acts by targeting 7,8-dihydro-8-oxoguanine triphosphatase (MTH1).
Oxcia is a pharmaceutical manufacturing company. Oxcia is headquartered in Stockholm, Sweden.
For a complete picture of OXC-101’s drug-specific PTSR and LoA scores, buy the report here.